Active substances set

Search phrase: encorafenib

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Colon and rectum cancer

Encorafenib	Encorafenib is indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy.	NO REIMBURSEMENT ESMO

Tracheal, bronchus, and lung cancer

Encorafenib	Non-small cell lung cancer (NSCLC) Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.	FULL REIMBURSEMENT ESMO